These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25502587)

  • 1. Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Thromb Thrombolysis; 2015 Aug; 40(2):131-8. PubMed ID: 25502587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    Clin Appl Thromb Hemost; 2016 Jan; 22(1):5-11. PubMed ID: 25993994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
    J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
    Wells PS; Lensing AWA; Haskell L; Levitan B; Laliberté F; Durkin M; Ashton V; Xiao Y; Crivera C; Lejeune D; Schein J; Lefebvre P
    J Med Econ; 2018 Jun; 21(6):587-594. PubMed ID: 29469638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials.
    Sardar P; Chatterjee S; Mukherjee D
    Drugs; 2013 Jul; 73(11):1171-82. PubMed ID: 23812923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
    Sobieraj DM; Coleman CI; Pasupuleti V; Deshpande A; Kaw R; Hernandez AV
    Thromb Res; 2015 May; 135(5):888-96. PubMed ID: 25795564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism.
    Kang N; Sobieraj DM
    Thromb Res; 2014 Jun; 133(6):1145-51. PubMed ID: 24713109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism.
    Yoon D; Jeong HE; Park S; You SC; Bang SM; Shin JY
    BMC Med; 2023 Sep; 21(1):375. PubMed ID: 37775786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
    Coleman CI; Limone BL; Bookhart BK; Mody SH; Nutescu EA
    Thromb Res; 2014 May; 133(5):743-9. PubMed ID: 24582461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism.
    Piovella F; Iosub DI
    Thromb Res; 2017 Apr; 152():87-92. PubMed ID: 28017344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New oral anticoagulants in patients with cancer: current state of evidence.
    Sardar P; Chatterjee S; Herzog E; Pekler G; Mushiyev S; Pastori LJ; Visco F; Aronow WS
    Am J Ther; 2015; 22(6):460-8. PubMed ID: 24800791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Efficacy and Safety Profiles of the Novel Oral Anticoagulants in the Treatment and Prevention of Venous Thromboembolism.
    Coulis AA; Mackey WC
    Clin Ther; 2018 Dec; 40(12):2140-2167. PubMed ID: 30409498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
    Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
    J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.